Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib for Pediatric Adenotonsillectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 2-18 years~* Tonsillectomy, or adenotonsillectomy~* No exclusion criteria~Exclusion Criteria:~* Age \< 2yrs and \>18yrs old~* BMI \< 10th or \> 95th percentile~* Serum creatinine (Cr) \> 2 X UNL (upper normal limit)~* Abnormal liver function; namely alanine aminotransferase (ALT) \> 1.5 X UNL, alkaline phosphatase (ALP) \> 5X UNL, total bilirubin \> 2 X UNL~* History of peptic ulcer disease.~* History of bleeding disorders~* History of severe asthma (requiring recent hospital admission or oral corticosteroid therapy)~* Allergy to celecoxib, sulfonamide compounds or NSAIDs~* Patients receiving CYP2C9 inhibitors fluconazole, amiodarone and oxandrolone~* Patients receiving CYP2C9 inducers rifampin and phenobarbital~* Extremes of body mass index (BMI) (age related below10th or above 90th percentile)~* Parents of any participants, irrespective of age, who are unable to read and understand instructions relayed in English or French~* Participant and/or parents of any participants, irrespective of age, who suffer from dementia, psychosis, significant developmental delay or other impairment that would prohibit the understanding and giving of informed consent or assent or the participation in self-care or toxicity reporting

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Celebrex suspension
- B (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).